Expertise in
26
conditions

Dr. Neil Korman

Dermatology
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
Offers Telehealth
Expertise in
26
conditions
University Hospitals
11100 Euclid Ave, 
Cleveland, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Neil Korman is a Dermatologist in Cleveland, Ohio. Dr. Korman is highly rated in 26 conditions, according to our data. His top areas of expertise are Psoriasis, Plaque Psoriasis, Bullous Pemphigoid, and Pemphigus.

His clinical research consists of co-authoring 77 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
SummaCare
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 24 Less Insurance Carriers -

Locations

University Hospitals
11100 Euclid Ave, Cleveland, OH 44106
Call: 216-844-8200

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Phase 2a Prospective, Randomized, Double-blind, Intra-subject, Placebo-controlled, Proof of Concept Study to Evaluate the Efficacy of OLX10010 as an Adjunct Therapy to Reduce the Recurrence of Hypertrophic Scars After Scar Revision Surgery
Enrollment Status: Completed
Publish Date: February 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug
Study Drug: LY3041658
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 2
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 28, 2022
Intervention Type: Drug
Study Drug: Naloxone Hydrochloride Lotion
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 13 Less Clinical Trials

77 Total Publications

Association Between Hurley Stage and Comorbidities in Hidradenitis Suppurativa.
Association Between Hurley Stage and Comorbidities in Hidradenitis Suppurativa.
Journal: International journal of dermatology
Published: September 25, 2025
View All 77 Publications
Similar Doctors
Wilma Bergfeld
Expertise in
74
conditions
Dr. Wilma Bergfeld
Dermatology
Expertise in
74
conditions
Dr. Wilma Bergfeld
Dermatology

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.6 miles away)
216-444-2200
Experience:
66+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Wilma Bergfeld is a Dermatologist in Cleveland, Ohio. Dr. Bergfeld has been practicing medicine for over 66 years is highly rated in 74 conditions, according to our data. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Graham-Little-Piccardi-Lassueur Syndrome, Alopecia Areata, Squamous Cell Skin Carcinoma, and Osteotomy.

Anthony Fernandez
Expertise in
93
conditions
Dr. Anthony Fernandez
Dermatology
Expertise in
93
conditions
Dr. Anthony Fernandez
Dermatology

Cleveland Clinic Main Campus

2049 East 100th Street, 
Cleveland, OH 
 (0.6 miles away)
216-444-2200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Fernandez is a Dermatologist in Cleveland, Ohio. Dr. Fernandez is highly rated in 93 conditions, according to our data. His top areas of expertise are Dermatomyositis, Pyoderma Gangrenosum, Acute Febrile Neutrophilic Dermatosis, and Calciphylaxis.

Expertise in
79
conditions
Dr. Kord Honda
Dermatology
Expertise in
79
conditions
Dr. Kord Honda
Dermatology

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
216-844-8200
Languages Spoken:
English
See accepted insurances

Kord Honda is a Dermatologist in Cleveland, Ohio. Dr. Honda is highly rated in 79 conditions, according to our data. His top areas of expertise are Melanoma, Erythroderma, Acrogeria, Gottron Type, and Stiff Skin Syndrome.

VIEW MORE Dermatologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Korman's expertise for a condition
ConditionClose
  • Elite
  • Plaque Psoriasis
    Dr. Korman is
    Elite
    . Learn about Plaque Psoriasis.
    See more Plaque Psoriasis experts
  • Psoriasis
    Dr. Korman is
    Elite
    . Learn about Psoriasis.
    See more Psoriasis experts
  • Distinguished
  • Bullous Pemphigoid
    Dr. Korman is
    Distinguished
    . Learn about Bullous Pemphigoid.
    See more Bullous Pemphigoid experts
  • Cicatricial Pemphigoid
    Dr. Korman is
    Distinguished
    . Learn about Cicatricial Pemphigoid.
    See more Cicatricial Pemphigoid experts
  • Hidradenitis Suppurativa
    Dr. Korman is
    Distinguished
    . Learn about Hidradenitis Suppurativa.
    See more Hidradenitis Suppurativa experts
  • Pemphigus
    Dr. Korman is
    Distinguished
    . Learn about Pemphigus.
    See more Pemphigus experts
  • Pemphigus Foliaceus
    Dr. Korman is
    Distinguished
    . Learn about Pemphigus Foliaceus.
    See more Pemphigus Foliaceus experts
  • Pemphigus Vulgaris
    Dr. Korman is
    Distinguished
    . Learn about Pemphigus Vulgaris.
    See more Pemphigus Vulgaris experts
View All 8 Distinguished Conditions
  • Advanced
  • Alopecia Areata
    Dr. Korman is
    Advanced
    . Learn about Alopecia Areata.
    See more Alopecia Areata experts
  • Atopic Dermatitis
    Dr. Korman is
    Advanced
    . Learn about Atopic Dermatitis.
    See more Atopic Dermatitis experts
  • Autosomal Recessive Hypotrichosis
    Dr. Korman is
    Advanced
    . Learn about Autosomal Recessive Hypotrichosis.
    See more Autosomal Recessive Hypotrichosis experts
  • Cerebral Cavernous Malformation
    Dr. Korman is
    Advanced
    . Learn about Cerebral Cavernous Malformation.
    See more Cerebral Cavernous Malformation experts
  • Cherry Angioma
    Dr. Korman is
    Advanced
    . Learn about Cherry Angioma.
    See more Cherry Angioma experts
  • Comedones
    Dr. Korman is
    Advanced
    . Learn about Comedones.
    See more Comedones experts
View All 16 Advanced Conditions
  • Experienced
  • Acne
    Dr. Korman is
    Experienced
    . Learn about Acne.
    See more Acne experts
  • Acrokeratoelastoidosis of Costa
    Dr. Korman is
    Experienced
    . Learn about Acrokeratoelastoidosis of Costa.
    See more Acrokeratoelastoidosis of Costa experts
  • Actinic Keratosis
    Dr. Korman is
    Experienced
    . Learn about Actinic Keratosis.
    See more Actinic Keratosis experts
  • Alopecia Universalis
    Dr. Korman is
    Experienced
    . Learn about Alopecia Universalis.
    See more Alopecia Universalis experts
  • Athlete's Foot
    Dr. Korman is
    Experienced
    . Learn about Athlete's Foot.
    See more Athlete's Foot experts
  • Autosomal Recessive Cutis Laxa Type 1
    Dr. Korman is
    Experienced
    . Learn about Autosomal Recessive Cutis Laxa Type 1.
    See more Autosomal Recessive Cutis Laxa Type 1 experts
View All 92 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Dermatologists Cleveland, OH
  3. Dr. Neil Korman
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.